Arizona Tribune - Boulevard

NYSE - LSE

RBGPF	0.33%	61.5	$
AZN	0.63%	189.6	$
BP	1.05%	37.525	$
RYCEF	0.05%	18.76	$
BTI	-0.56%	62.41	$
BCE	-1.87%	22.5	$
RIO	-0.05%	93.69	$
RELX	-0.06%	31.32	$
GSK	-0.21%	52.39	$
VOD	-1.65%	13.665	$
CMSD	0.07%	21.785	$
CMSC	0.32%	22	$
BCC	-2.95%	78.695	$
JRI	0.72%	12.883	$
NGG	0.41%	83.35	$

Featured

Five shot dead at German youth welfare site, two suspects arrested

Five people were shot dead at a youth welfare facility in Germany on Monday and the suspected gunman was arrested, police said, in one of the country's deadliest shootings in years.

Chavez-era housing complex in ruins after Venezuela quakes

A residential complex once touted as part of former strongman leader Hugo Chavez's flagship housing program has been left uninhabitable in Venezuela's earthquake disaster.

Last news

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023$20.4 million cash balance at December 31, 2024Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time

New to the Street Announces 12-Month Partnership With ROADZEN - Monthly Fox Business & Bloomberg Coverage, Earned Media, TV Commercials, and Times Square Billboards

In addition to long-form coverage, New to The Street will also be producing and broadcasting Roadzen commercials on CNBC and FOX Business Network during market hours, as well as across Bloomberg Television and FOX Business during its sponsored programming. This multi-platform strategy will deliver unparalleled exposure for Roadzen's AI-driven auto insurance solutions.

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Investor Call and Webcast Scheduled for 4:30 P.M ET

TPT Global Tech Announces SEC Filing Compliance and Reaffirms Commitment to Shareholders

SAN DIEGO, CA / ACCESS Newswire / February 12, 2025 / TPT Global Tech, Inc. (OTC PINK:TPTW) today announced that it is now fully compliant with all Securities and Exchange Commission (SEC) filing requirements. This achievement reflects the company's commitment to transparency, financial integrity, and delivering long-term value to its shareholders.

The International Roofing Expo Returns to San Antonio with Fresh Content and Expanded Exhibit Space, Energizing the Roofing and Exteriors Community

IRE is the industry's annual hub for products, equipment, hands-on education and networking.

Interactive Strength Inc. (Nasdaq:TRNR) CEO Confirms Sportstech Acquisition and Shares Future Acquisition Strategy at Connected: Health & Fitness Summit

Trent Ward, Ali Ahmad and Mohammed Iqbal Unpack Tailwinds and Major Opportunities in Fragmented Health & Wellness Market During Fireside ChatCompany Also Provides Shareholder Update

Dolphin Leads Major Brand Activations During Super Bowl LVIII

Observer's 2025 #1 Agency of the Year Showcases its Award-Winning Marketing Prowess Across Advertising, Live Events, and Social Media

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

The FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions where there is an unmet medical need. FAP, an inherited condition that puts people at a much greater risk of developing colon cancer, falls into that category. The condition is typically diagnosed in the early teenage years and results in a nearly 100% lifetime risk of colorectal cancer.

CTT Pharma Gives Update On NSF Grant

TAMPA, FL / ACCESS Newswire / February 12, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal to the National Science Foundation(NSF) for our patented fast dissolving nicotine strips. The NSF grant program is highly competitive as it receives over 12,000 applicants annually from companies that have innovations that could help society. CTT successfully made it past the first round process and is among a few thousand remaining applicants. These remaining applicants have several deadlines over the course of the year to file a full proposal into the grant program. CTT is anticipating an answer in this program in late April. Acceptance into this program would give government backing to CTT Pharma and would allow for extensive research and testing to help lead to development of our technology.

Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

Relocation to More Efficient Space Supports Growth While Reducing Overhead by Over $200,000 Annually

Dozens evacuated as fire breaks out in 50-floor building in Buenos Aires

Dozens of people were evacuated as a fire broke out in a 50-story Buenos Aires apartment building Tuesday without claiming any lives, emergency services personnel in the Argentine capital said.

Rushdie tells trial of 'lake of blood' after stabbing

Novelist Salman Rushdie described Tuesday the moment a knife-wielding attacker stormed on stage and attempted to kill him with a frenzied attack that left him blind in one eye.

US funding freeze is 'bombshell' for world aid sector

US President Donald Trump's order to suspend most foreign aid has sent shock waves through the humanitarian sector, threatening to trigger mass layoffs at many NGOs and possibly destroy others altogether.

Malaysia's Hindus mark Thaipusam festival with fervour

Hundreds of thousands of Hindus flocked to temples across Malaysia to celebrate the Thaipusam festival Tuesday, with many piercing their bodies with hooks and skewers in acts of devotion.

Philippine divorce activists vow to fight on

In her bid to convince lawmakers to legalise divorce, Filipina fruit vendor Avelina Anuran has publicly testified about the abuse she said she regularly endured at the hands of her husband.

Early Detection Of Breast Cancer Seen As A Benefit With Seated Option in the VELA Mammography Chair, Enable Me Finds in Technologist Survey

"The handicapped and the elderly can be put at ease, and better images obtained with the use of this chair. I would highly recommend every facility that performs mammograms have one of these available for use with their patients."

AI Takes Center Stage at NAB Show with New FBRC.ai Partnership

Discover AI innovation, Trends and Challenges Across the Industry

vVARDIS Announces $35 Million Financing with Global Healthcare Investor OrbiMed to Roll Out Curodont, an Innovative Drill-Free Treatment for Early Tooth Decay

ZUG, SWITZERLAND / ACCESS Newswire / February 11, 2025 / vVARDIS, a Swiss high growth dental company, and OrbiMed, a leading healthcare investment firm, today announced the closing of a $35 million financing. The capital will support the company's growth initiatives and global commercial expansion. vVARDIS is a developer and manufacturer of unique dental products under the Curodont brand, including their innovative drill-free treatment for early tooth decay. Today tooth decay remains number one disease in the world according to the World Health Organization. Last year's rapid expansion of sales, with an initial focus on the U.S., already has thousands of dental clinics using the product and over 300,000 teeth treated in 2024. vVARDIS' technology is already incorporated in lectures of renowned universities in the U.S. and Europe as a new standard of care for the treatment of early tooth decay.

The Water & Wastewater Equipment, Treatment and Transport (WWETT) Show Announces Inaugural Young Professionals Award Winners

INDIANAPOLIS, IN / ACCESS Newswire / February 11, 2025 / The WWETT Show, the world's largest annual tradeshow for wastewater and environmental services professionals, proudly announces the recipients of its inaugural Young Professionals Award program.

CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 2024

Uncertain outlook for 2025 as new immigration policies are implemented

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Finalizing scale-up production phaseEngaging with Contract Research Organizations to complete the technical dossierClinical trials expected to complete in late 2025 or early 2026Potential classification as a Class III medical deviceProduct launch expected in the first or second quarter of 2026Further updates on progress to follow in the coming months

PUPS Pet Club Brings Premier Dog Care Services to Chicago's Vibrant Lakeshore East Community

PUPS' Seventh Chicago Location Offers Urban Pet Parents Convenient, Health Club Quality Pet Care

Boomerang Ventures Completes Series A2 Round in Wicked Technologies to Advance Incontinence Care Innovation

INDIANAPOLIS, IN / ACCESS Newswire / February 11, 2025 / Boomerang Ventures, a combination venture studio and fund, has completed a $2.1 million Series A2 funding round for Wicked Technologies, a Louisville-based company revolutionizing incontinence care with its Wicked Smart Pad™ (WSP). This investment marks Boomerang Ventures' latest commitment to investing in women-led health technology innovations that are set to revolutionize patient care.

Cellev8 Nutrition(TM) and NFL Legend Andre Reed Launch Groundbreaking Partnership at Super Bowl, Revolutionizing Cellular Health in Sports

Cellev8 Continues to breakthrough, enhance and improve the lives of athletes globally

John Muir Health Announces the Full Enterprise Rollout of Ambience Healthcare's AI Platform

Ambience's fully Epic-integrated AI technology reduces burnout and boosts patient face time

Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14

STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m.

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Additions broaden DehydraTECH patent suite for Epilepsy

Jerash Holdings Reports Fiscal 2025 Third Quarter Financial Results

FAIRFIELD, NJ / ACCESS Newswire / February 11, 2025 / Jerash Holdings (US), Inc. ("Jerash" or the "Company") (NASDAQ:JRSH), which manufactures and exports custom, ready-made, sportswear and outerwear for leading global brands, today announced financial results for its fiscal 2025 third quarter, ended December 31, 2024.

Every Day, an Independent Pharmacy Shuts Down - ATRIUMX Helps Owners Take Control

New Conference format poised to support Community Pharmacy

Interactive Strength Inc. (Nasdaq:TRNR) Signs Binding Agreement to Acquire Sportstech, a Profitable $40M+ Revenue Connected-Fitness Equipment Business

TRNR is expected to generate more than $50M in revenue in 2025 on a pro forma basis and achieve EBITDA profitability in H2 ‘25Sportstech is founder-led, having achieved profitability and scale without raising capital and has successfully sold equipment to almost 3 million customers since 2012TRNR Listing and global presence to help Sportstech accelerate growth beyond core markets, most notably the US; Sportstech's scaled, profitable business to drive step-change for TRNR top and bottom linesTransaction delivers on previously-announced LOI, combines highly complementary businesses to create a scaled, international operation anchored in the US and Germany, the #1 and #2 fitness markets globallyDeal - TRNR's second within 12 months - advances its strategy for building shareholder value through accretive acquisitions of profitable, growth businesses in the fragmented global health & wellness marketTRNR CEO to discuss transaction at 2025 Connected: Health & Fitness Summit today in Los Angeles

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.

BioVersys Successfully Advances Bv500 NTM Program with Continued Support from CF AMR Syndicate

BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against non-tuberculous mycobacteria (NTM).Continued strategic support from LifeArc through the CF AMR Syndicate Collaborative Discovery Programme (CDP), accelerating the development of novel therapies for difficult-to-treat NTM lung disease in cystic fibrosis (CF) patients.Leveraging its proprietary Ansamycin Chemistry platform, BioVersys' BV500 molecules are designed to overcome resistance and address highly drug-resistant NTM infections.

Arizona Tribune - Boulevard (English)